Get the Stockscreener App
4.66
2.87%
0.13
Pre-market:
4.60
-0.06
-1.29%
Pepgen Inc stock is traded at $4.66, with a volume of 676.18K.
It is up +2.87% in the last 24 hours and up +0.87% over the past month.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
See More
Previous Close:
$4.53
Open:
$4.49
24h Volume:
676.18K
Relative Volume:
0.24
Market Cap:
$152.85M
Revenue:
-
Net Income/Loss:
$-87.23M
P/E Ratio:
-1.569
EPS:
-2.97
Net Cash Flow:
$-82.77M
1W Performance:
+1.97%
1M Performance:
+0.87%
6M Performance:
+196.82%
1Y Performance:
-29.61%
1-Day Range:
$4.3834
$4.72
1-Week Range:
$4.3834
$5.6492
52-Week Range:
$0.8801
$7.50
Pepgen Inc Stock (PEPG) Company Profile
Name
Pepgen Inc
Sector
Industry
Phone
703-456-8000
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
4.66 | 311.38M | 0 | -87.23M | -82.77M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Initiated | Guggenheim | Buy |
| Dec-16-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-21-22 | Initiated | H.C. Wainwright | Buy |
Pepgen Inc Stock (PEPG) Latest News
PepGen to Participate in Upcoming Investor Conferences - The AI Journal
Will PepGen Inc. continue its uptrendJuly 2025 Selloffs & Weekly Watchlist for Consistent Profits - newser.com
Tools to monitor PepGen Inc. recovery probabilityWeekly Stock Report & AI Forecasted Entry/Exit Points - newser.com
What risks investors should watch in PepGen Inc. stock2025 Macro Impact & Verified Momentum Watchlists - newser.com
Detecting price anomalies in PepGen Inc. with AI2025 Earnings Impact & Technical Pattern Recognition Alerts - newser.com
Bronstein, Gewirtz & Grossman, LLC Encourages PepGen Inc. (PEPG) Investors to Inquire about Securities Investigation - ACCESS Newswire
Advanced analytics toolkit walkthrough for PepGen Inc.July 2025 Macro Moves & Weekly Consistent Profit Watchlists - newser.com
Is PepGen Inc. stock trading near support levelsTrade Signal Summary & Technical Pattern Alert System - newser.com
What margin trends mean for PepGen Inc. stockProduct Launch & High Return Trade Opportunity Guides - newser.com
Why PepGen Inc. stock is favored by pension fundsWeekly Profit Analysis & Real-Time Chart Pattern Alerts - newser.com
Using flow based indicators on PepGen Inc.Quarterly Performance Summary & High Yield Equity Trading Tips - newser.com
BofA Lifts PepGen (PEPG) PT to $3 on Positive DM1 Data Despite Underperform Rating - MSN
PepGen (PEPG) to Release Earnings on Thursday - MarketBeat
Will PepGen Inc. stock sustain high P E ratiosWeekly Profit Report & Safe Capital Growth Stock Tips - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against PepGen Inc. (PEPG) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Will PepGen Inc. stock see insider buyingWeekly Market Report & Free High Return Stock Watch Alerts - newser.com
PepGen: Moving To "Hold" Rating On Best Mean Splicing Correction In DM1 Testing (PEPG) - Seeking Alpha
PepGen Inc. (PEPG) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
HC Wainwright Boosts PepGen (NASDAQ:PEPG) Price Target to $18.00 - MarketBeat
PepGen price target raised to $18 from $12 at H.C. Wainwright - MSN
HC Wainwright & Co. Maintains PepGen (PEPG) Buy Recommendation - Nasdaq
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
PepGen Inc. Advances DM1 Treatment with New Clinical Study - MSN
PepGen’s PGN-EDODM1 Study: A Potential Breakthrough for Myotonic Dystrophy Type 1 - TipRanks
Is PepGen Inc. stock attractive after correctionInsider Selling & Fast Entry High Yield Tips - fcp.pa.gov.br
Dyne, PepGen jump as potential beneficiaries of Novartis/Avidity deal (DYN:NASDAQ) - Seeking Alpha
Novartis Deal Lifts Avidity, Domino Effect Boosts Dyne And PepGen - RTTNews
Pepgen Inc Stock (PEPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):